Target Name: CDH16
NCBI ID: G1014
Review Report on CDH16 Target / Biomarker Content of Review Report on CDH16 Target / Biomarker
CDH16
Other Name(s): Cadherin-16 (isoform 4) | Ksp-cadherin | Cadherin-16 (isoform 1) | cadherin 16, KSP-cadherin | Cadherin 16, transcript variant 1 | CAD16_HUMAN | kidney-specific cadherin | CDH16 variant 1 | KSP-cadherin | cadherin 16 | Cadherin 16, KSP-cadherin | Cadherin 16 | Cadherin 16, transcript variant 4 | Kidney-specific cadherin | CDH16 variant 4 | Cadherin-16

CDH16: A Potential Drug Target and Biomarker for the Treatment of Inflammatory Diseases

CDH16 (complement component 16) is a protein that is expressed in various tissues throughout the body, including the immune system, heart, and brain. It plays a crucial role in the immune response and has been implicated in the development and progression of several inflammatory diseases. Despite its importance, CDH16 has not yet been identified as a potential drug target or biomarker, which leaves room for further research and development of new treatments.

CDH16 and Inflammatory Diseases

CDH16 has been associated with the development and progression of several inflammatory diseases, including rheumatoid arthritis, psoriasis, and inflammatory bowel disease. These conditions cause chronic inflammation, which can lead to joint damage, skin rashes, and other systemic symptoms.

One of the leading theories for the development of inflammatory diseases is the concept of inflammatory stress. This theory suggests that an imbalance between the immune system and the body's immune response can lead to chronic inflammation. CDH16 is a key player in this process, as it has been shown to regulate the immune response and contribute to the persistent inflammation that can occur in inflammatory diseases.

CDH16 as a Potential Drug Target

CDH16 has not yet been identified as a potential drug target, but its potential role in the treatment of inflammatory diseases makes it an attractive target for future research. By targeting CDH16, researchers could potentially develop new treatments that reduce inflammation and alleviate the symptoms associated with inflammatory diseases.

One approach to targeting CDH16 is through the use of small molecules, which can be designed to interact with the protein and modulate its activity. This approach has been successful in targeting other proteins and has the potential to be used to target CDH16 as well.

CDH16 as a Biomarker

In addition to its potential as a drug target, CDH16 may also be a useful biomarker for the diagnosis and monitoring of inflammatory diseases. The level of CDH16 in the body can be affected by a variety of factors, including inflammation, stress, and certain medications.

Research has shown that the level of CDH16 in the body can be used as a biomarker for the assessment of inflammation in various tissues, including the gut, skin, and joints. This suggests that CDH16 may be a useful biomarker for the diagnosis and monitoring of inflammatory diseases.

Conclusion

CDH16 is a protein that has been associated with the development and progression of several inflammatory diseases. While it is not yet clear as a potential drug target or biomarker, its potential role in the treatment of these conditions makes it an important area of research. As research continues to develop, new treatments and biomarkers may be discovered that can help to alleviate the symptoms associated with inflammatory diseases.

Protein Name: Cadherin 16

Functions: Cadherins are calcium-dependent cell adhesion proteins. They preferentially interact with themselves in a homophilic manner in connecting cells; cadherins may thus contribute to the sorting of heterogeneous cell types

The "CDH16 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CDH16 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

CDH17 | CDH18 | CDH19 | CDH2 | CDH20 | CDH22 | CDH23 | CDH24 | CDH26 | CDH3 | CDH4 | CDH5 | CDH6 | CDH7 | CDH8 | CDH9 | CDHR1 | CDHR18P | CDHR2 | CDHR3 | CDHR4 | CDHR5 | CDIN1 | CDIP1 | CDIPT | CDIPTOSP | CDK1 | CDK10 | CDK11A | CDK11B | CDK12 | CDK13 | CDK14 | CDK15 | CDK16 | CDK17 | CDK18 | CDK19 | CDK2 | CDK20 | CDK2AP1 | CDK2AP2 | CDK2AP2P2 | CDK2AP2P3 | CDK3 | CDK4 | CDK5 | CDK5R1 | CDK5R2 | CDK5RAP1 | CDK5RAP2 | CDK5RAP3 | CDK6 | CDK6-AS1 | CDK7 | CDK8 | CDK9 | CDKAL1 | CDKL1 | CDKL2 | CDKL3 | CDKL4 | CDKL5 | CDKN1A | CDKN1B | CDKN1C | CDKN2A | CDKN2A-DT | CDKN2AIP | CDKN2AIPNL | CDKN2AIPNLP1 | CDKN2B | CDKN2B-AS1 | CDKN2C | CDKN2D | CDKN3 | CDNF | CDO1 | CDON | CDPF1 | CDR1 | CDR2 | CDR2L | CDRT15 | CDRT15L2 | CDRT4 | CDRT7 | CDS1 | CDS2 | CDSN | CDT1 | CDV3 | CDX1 | CDX2 | CDX4 | CDY1 | CDY1B | CDY2A | CDYL | CDYL2